Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Oncothyreon Inc. announced that the first patient has been treated in a Phase 1b clinical trial of PX-12 in patients with advanced metastatic cancer. PX-12 is a proprietary small molecule inhibitor of thioredoxin, a protein that regulates diverse molecular pathways that contribute to the growth, survival and drug resistance of many cancers.
The primary objective of the Phase 1b dose-escalation trial is to determine the safety and tolerability of a 72-hour continuous infusion of PX-12 given on the first three days of a 21-day cycle. Other objectives of the trial include an evaluation of the pharmacokinetics and pharmacodynamics of the prolonged infusion, together with identification of any anti-tumor activity. The trial is expected to enroll up to 28 patients at three centers in the United States.
Other news from the department research and development
